[HTML][HTML] A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
S Verstovsek, S Courby, M Griesshammer, RA Mesa… - Leukemia research, 2017 - Elsevier
Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients
with primary and secondary myelofibrosis. This phase 2, open-label, randomized study
evaluated the efficacy and safety of oral once-daily momelotinib (100 mg and 200 mg) for
the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The primary
endpoint for PV was overall response rate (ORR), defined as the proportion of patients with
hematocrit< 45%, white blood cell count< 10× 10 9/L, platelet count≤ 400× 10 9/L, and …
with primary and secondary myelofibrosis. This phase 2, open-label, randomized study
evaluated the efficacy and safety of oral once-daily momelotinib (100 mg and 200 mg) for
the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The primary
endpoint for PV was overall response rate (ORR), defined as the proportion of patients with
hematocrit< 45%, white blood cell count< 10× 10 9/L, platelet count≤ 400× 10 9/L, and …